ABUS vs CLX · P/E 5.4, rev $6.2M vs P/E 15, rev $7.10B
Arbutus Biopharma Corp (ABUS) versus The Clorox Company (CLX) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
The Clorox Company (CLX) is a household & personal products company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CLX revenue for 2025-06-30 was $7.10B. Net income was $824.0M. Revenue was up 0.2% from 2024-06-30 to 2025-06-30. CLX currently screens at market cap $10.89B and trailing P/E 14.6.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CLX currently screens at market cap $10.89B and trailing P/E 14.6.
Not investment advice. Open the ABUS and CLX stock pages for the full models.
Not investment advice.